The strongest verified fact: one biotech that does not need the market
Incyte Corporation reported cash of $3,275,881,000 for Q3 2026, according to its SEC filing.1 Two years earlier the picture was very different. At Q2 2024 the same filing line showed $987,293,000, and at Q3 2024 it showed $1,304,109,000.1 The company then rebuilt it: $1,941,722,000 at Q1 2025, $2,455,006,000 at Q3 2025, $3,097,817,000 for fiscal 2025, $3,461,114,000 at Q1 2026 and $3,982,375,000 at Q2 2026.1 The Q3 2026 figure of about $3.28 billion is below the Q2 2026 peak of about $3.98 billion.1
Two cautions apply. The dossier does not say why the Q3 2026 figure is lower than Q2. We will not guess whether that was spending, a deal or a reclassification. The data also does not say whether this “cash” line includes short-term investments, which could explain some of the large swings. For a reader deciding how much cushion a company has, that definition matters, and we have not verified it.
Why lead with this? The question for biotech investors this month is whether money stays available while technology stocks fall. A company holding more than $3 billion in cash, on the filed numbers, is not asking anyone for money this quarter. That is the opposite of the position of a pre-trial company, which we turn to below.
The cost side: what it takes to sell medicines
Incyte's cost of revenue, the direct cost of producing what it sells, rose from $254,990,000 in fiscal 2023 to $312,068,000 in fiscal 2024 and $372,130,000 in fiscal 2025.2 The quarterly numbers show the same climb. Q1 2025 was $73,188,000 and Q1 2026 was $104,523,000. Q2 2025 was $78,766,000 and Q2 2026 was $104,957,000. Q3 2025 was $99,001,000 and Q3 2026 was $108,744,000.2 The jump was steepest in the first half of the year, and the Q3 gap against last year was much narrower.
This set of verified facts contains cost of revenue but no revenue line. We therefore cannot say whether margins are widening or narrowing, and we will not infer it. Capital spending was $48,700,000 in both fiscal 2024 and fiscal 2025.3 That is identical to the dollar across two years, and we report it as filed. Earnings per share is the other thin spot. The only figure in our verified set is $2.65 per share for fiscal 2023.4 Treat the Incyte picture as a strong balance sheet with an incomplete income statement.
Clinical results that carry financial weight
Vor Bio announced final two-year Phase 3 TELIGAN results for telitacicept in IgA nephropathy, a kidney disease. Treated patients showed an annualized kidney-function (eGFR) slope of -0.6, against -5.7 mL/min/1.73 m²/year for placebo. That is a 5.1 difference, with p<0.001. The company also reported 89% and 81% reductions in the risk of confirmed 30% and 40% eGFR declines.5 These are the company's own figures, from its press release of October 22, 2026. The wire service that carried it has a measured record of 54% of 6,613 checked claims holding up, so treat it as a primary-source announcement and not an independent finding.5
Royalties show how a successful drug turns into reliable cash for a smaller partner. BioArctic said Eisai recorded Leqembi sales of JPY 29.3 billion in Q2 2026, which produced a BioArctic royalty of SEK 179 million, up about 10 percent on Q2 2025.6 The year-earlier quarter contained a one-time Chinese stockpiling effect of around JPY 5.3 billion. BioArctic stated: “Excluding the stockpiling effect, royalty revenues in Q2 2026 grew approximately 43 percent compared to the same quarter last year.”6 The gap between 10 percent and 43 percent is the lesson. Headline growth can understate or overstate the underlying trend depending on a single odd comparison period.
A smaller signal comes from insiders. UroGen's Chief Medical Officer, Mark Schoenberg, sold 10,000 ordinary shares for a total value of $400,000 on July 9, 2026.7 The report said the sale ran under a pre-established Rule 10b5-1 plan adopted on August 15, 2025, and was the concluding transaction of that plan's schedule.7 Pre-scheduled sales are a weak signal about what an executive thinks of the stock, and the plan date shows this one was decided long before the 191% run the headline describes.7
Pre-revenue companies live on timelines, and on capital
The companies below do not have Incyte's cushion in our data. We hold no cash figures for them, so this is a description of dependency, not a finding about their finances. Ernexa Therapeutics said it remained on schedule to submit its IND application for ERNA-101 in the third quarter of 2026, with a first-in-human Phase 1 trial anticipated in the fourth quarter.8 Prelude Therapeutics expected an IND submission for PRT13722 by mid-2026 and a Phase 1 study in ER-positive breast cancer in the second half of 2026.9 Akari Therapeutics pointed to planned Phase 1 development of AKTX-101 in mid-2027. It also argued that “ADC-refractory patients are a significant, growing unmet need and an exclusive opportunity for Akari's novel payload.”10 Two of these come from promotional wire items with measured reliability of 35% and 54%, which is another reason to treat the timelines as intentions, not milestones.8,10
Hiring points the same way. Idorsia appointed Begoña Carreño-Gómez as Chief Business Development Officer, effective November 1, 2026.11 Companies add deal-makers when they expect to license, sell or partner assets, and that work depends on buyers having money.
The AI-bio claims need a lower weight
Radical Numerics said AI-designed viruses had treated its first patient, in an experimental treatment targeting drug-resistant E. coli.12 Separately, Generation Lab said its treatment “blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues.”13 Both items reached us through MIT Technology Review items whose measured reliability is low: 6% of 16 checked claims held up.12,13 The Generation Lab wording is a company fact sheet being quoted, not a result. The dossier holds nothing on trial data, price or funding for either company.
The topic also mentioned an AI agent that performed a brain injection and strong Eli Lilly GLP-1 demand. Our verified set contains nothing that supports figures for either, so we make no claims about them.
The backdrop: money for AI is getting harder
On October 30, 2026 a $1 trillion technology selloff deepened fears of an AI bubble. Big AI bills and weak earnings spooked investors, and the Nasdaq 100 had its worst day since June.14 The next day OpenAI cut its funding target by $10 billion.15 On November 1, Binance users withdrew $3.6 billion when the exchange reopened after a hack.16 The Nasdaq 100 is a common index-fund holding, so many ordinary portfolios felt the first of these directly. The dossier does not give the index weights, so we do not attempt to measure how much.
Via News's analysis of this data is that the story splits into two kinds of company. Businesses with large filed cash balances, such as Incyte, can fund their own pipelines. Early-stage companies that promise IND filings and first-in-human trials, and especially those that wrap them in AI language, depend on outside capital that is now being questioned in neighbouring markets. This is our reading, not a measured link. Nothing in the dossier shows a biotech deal being pulled or repriced because of the selloff.
What to watch
- Whether Incyte's next filing explains the move in cash from about $3.98 billion to about $3.28 billion, and whether revenue rises in step with cost of revenue.
- Whether Ernexa's fourth-quarter Phase 1 start and Prelude's second-half study start actually happen on schedule.
- Whether further funding targets in AI are cut, since OpenAI's $10 billion reduction is so far the only one in our data.
- Independent confirmation for the Radical Numerics treatment, from sources with stronger records than the ones we have.
